TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation for Childhood Rhabdomyosarcoma
Source: Childhood Rhabdomyosarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 11, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Childhood Rhabdomyosarcoma
Information about NCI-supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
ARST2032 (NCT05304585) (Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low-Risk, Fusion-Negative Rhabdomyosarcoma): The COG redefined low-risk rhabdomyosarcoma using both clinical and molecular criteria. The new criteria will be used in this study. Patients are required to enroll in the COG APEC14B1 trial and the Molecular Characterization Initiative. Low-risk patients have both fusion-negative and wild-type MYOD1 and TP53. In this trial, very low-risk patients will receive 24 weeks of VA therapy, and low-risk patients will receive four cycles of VAC followed by VA for a total of 24 weeks.
Source links and citations
ARST2032 (NCT05304585) (Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low-Risk, Fusion-Negative Rhabdomyosarcoma): The COG redefined low-risk rhabdomyosarcoma using both clinical and molecular criteria. The new criteria will be used in this study. Patients are required to enroll in the COG APEC14B1 trial and the Molecular Characterization Initiative. Low-risk patients have both fusion-negative and wild-type MYOD1 and TP53. In this trial, very low-risk patients will receive 24 weeks of VA therapy, and low-risk patients will receive four cycles of VAC followed by VA for a total of 24 weeks.
| Subset | Fusion status | Tumor Site | Tumor Size | Surgical-pathological Group | MYOD1 or TP53 Status |
|---|---|---|---|---|---|
| Very Low Risk | Negative | Favorable | Any | I | Wild-type |
| Low Risk | Negative | Favorable | Any | II | Wild-type |
| Unfavorable | >5 cm | I, II | |||
| Orbit | Any | III |
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice